Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics


Lexicon Pharmaceuticals, Inc. (LXRX): $2.26

0.12 (+5.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LXRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LXRX POWR Grades

  • LXRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.85% of US stocks.
  • LXRX's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • LXRX ranks lowest in Momentum; there it ranks in the 4th percentile.

LXRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for LXRX is 0 -- better than only 6.99% of US stocks.
  • LXRX's price/sales ratio is 3,049.81; that's higher than the P/S ratio of 99.82% of US stocks.
  • Revenue growth over the past 12 months for LEXICON PHARMACEUTICALS INC comes in at -74.12%, a number that bests just 2.26% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to LXRX, based on their financial statements, market capitalization, and price volatility, are SPCE, PXLW, CDXS, MRNS, and CLGN.
  • Visit LXRX's SEC page to see the company's official filings. To visit the company's web site, go to www.lexpharma.com.

LXRX Valuation Summary

  • In comparison to the median Healthcare stock, LXRX's price/sales ratio is 66900% higher, now standing at 3216.
  • Over the past 243 months, LXRX's price/sales ratio has gone up 3210.6.

Below are key valuation metrics over time for LXRX.

Stock Date P/S P/B P/E EV/EBIT
LXRX 2022-11-25 3216.0 2.8 -4.1 -4.3
LXRX 2022-11-23 3216.0 2.8 -4.1 -4.3
LXRX 2022-11-22 3352.0 2.9 -4.3 -4.5
LXRX 2022-11-21 3306.4 2.9 -4.3 -4.4
LXRX 2022-11-18 3352.0 2.9 -4.3 -4.5
LXRX 2022-11-17 3336.8 2.9 -4.3 -4.4

LXRX Growth Metrics

    Its year over year price growth rate is now at -58.52%.
  • Its 3 year net income to common stockholders growth rate is now at 9.97%.
  • Its 3 year cash and equivalents growth rate is now at 30.02%.
Over the past 52 months, LXRX's revenue has gone down $98,824,000.

The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.125 -90.11 -97.061
2022-06-30 0.109 -87.821 -96.796
2022-03-31 0.308 -85.279 -90.276
2021-12-31 0.298 -87.017 -87.758
2021-09-30 0.483 -98.428 -67.642
2021-06-30 7.094 -121.656 38.083

LXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
  • LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
  • SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.

The table below shows LXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 0.911 2.792
2021-03-31 0.071 0.915 -0.037
2020-12-31 0.089 0.920 -0.233
2020-09-30 0.101 0.917 -0.269
2020-06-30 0.824 0.992 0.131
2020-03-31 0.875 0.990 0.239

LXRX Price Target

For more insight on analysts targets of LXRX, see our LXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.67 (Moderate Buy)

LXRX Stock Price Chart Interactive Chart >

Price chart for LXRX

LXRX Price/Volume Stats

Current price $2.26 52-week high $4.72
Prev. close $2.14 52-week low $1.31
Day low $2.10 Volume 299,637
Day high $2.26 Avg. volume 874,398
50-day MA $2.20 Dividend yield N/A
200-day MA $2.29 Market Cap 426.52M

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio


Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.


LXRX Latest News Stream


Event/Time News Detail
Loading, please wait...

LXRX Latest Social Stream


Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34th Annual Piper Sandler Healthcare Conference5th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chie

Yahoo | November 28, 2022

Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k

Yahoo | November 15, 2022

Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6Significant benefits demonstrated on burning pain and on pain interference with sleepNo evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call and Webcast Today at 5:00pm ET Hosted by Lexicon Management THE WOODLANDS, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that full results from the RELIEF-DPN-1 trial of its investigatio

Yahoo | November 14, 2022

Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Lexicon Pharmaceuticals ( NASDAQ:LXRX ) Third Quarter 2022 Results Key Financial Results Net loss: US$23.4m (loss...

Yahoo | November 12, 2022

Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation for the Jefferies conference which will be available on-demand beginning at 7:55 am ET/12:55 pm GMT on Wednesday, November 16, 2022. The webcast will be available in the “Events”

Yahoo | November 11, 2022

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo 7.11%
3-mo -16.91%
6-mo 24.86%
1-year -50.66%
3-year -31.52%
5-year -78.37%
YTD -42.64%
2021 15.20%
2020 -17.59%
2019 -37.50%
2018 -32.79%
2017 -28.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.739 seconds.